Published in J Virol on February 01, 2003
Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. J Virol (2003) 1.26
The varicella-zoster virus genome. Curr Top Microbiol Immunol (2010) 1.02
Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule. J Virol (2004) 0.95
Monitoring prevalence of varicella-zoster virus clades in Germany. Med Microbiol Immunol (2010) 0.91
Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides. J Virol (2004) 0.90
Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother (2005) 0.89
The Varicella-zoster virus DNA encapsidation genes: Identification and characterization of the putative terminase subunits. Virus Res (2007) 0.87
Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models. J Virol (2005) 0.84
Characterization of the Varicella-zoster virus ORF25 gene product: pORF25 interacts with multiple DNA encapsidation proteins. Virus Res (2009) 0.81
Current and Potential Treatments for Ubiquitous but Neglected Herpesvirus Infections. Chem Rev (2014) 0.80
Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein. J Virol (2012) 0.79
The Varicella-zoster virus ORF54 gene product encodes the capsid portal protein, pORF54. Virus Res (2012) 0.78
Non-axial view of the varicella-zoster virus portal protein reveals conserved crown, wing and clip architecture. Intervirology (2014) 0.76
The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA. J Virol (2014) 0.76
Intermolecular Complementation between Two Varicella-Zoster Virus pORF30 Terminase Domains Essential for DNA Encapsidation. J Virol (2015) 0.75
The complete DNA sequence of varicella-zoster virus. J Gen Virol (1986) 16.00
Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun (1991) 6.25
Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med (1996) 4.36
The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J Virol (2001) 3.65
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc Natl Acad Sci U S A (1993) 2.55
Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol (1998) 2.53
Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol (1998) 2.41
Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene. Virology (1996) 2.26
Herpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation. J Virol (2001) 2.21
The herpes simplex virus type 1 UL6 protein is essential for cleavage and packaging but not for genomic inversion. Virology (1996) 2.05
The product of the UL6 gene of herpes simplex virus type 1 is associated with virus capsids. Virology (1995) 1.97
Development of a live attenuated varicella vaccine. Biken J (1975) 1.74
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol (2001) 1.59
Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J Infect Dis (2000) 1.40
Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J Virol (2000) 1.30
RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol (2001) 1.15
Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med (1991) 1.11
Varicella-zoster virus ORF61 deletion mutants replicate in cell culture, but a mutant with stop codons in ORF61 reverts to wild-type virus. Virology (1998) 1.10
Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs (1999) 1.03
Computer modeling of prototypic and aberrant nucleocapsids of varicella-zoster virus. Virology (1995) 0.87
Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation. Curr Pharm Des (2000) 0.87
Novel agents for the therapy of varicella-zoster virus infections. Expert Opin Investig Drugs (2000) 0.86
How should we measure pain in herpes zoster? Neurology (1995) 0.85
Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res (1999) 0.83
Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis (1998) 0.82
Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Neurology (1995) 0.81
How to measure and reduce the burden of zoster-associated pain. Scand J Infect Dis Suppl (1996) 0.79
The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus. Antiviral Res (2002) 0.78
Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues. Microbiol Immunol (1995) 0.78
Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Res (1995) 0.78
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest (2003) 4.14
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res (2009) 3.03
Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature (2011) 2.82
Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 2.77
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 2.15
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.05
Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science (2013) 2.00
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res (2010) 1.86
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother (2005) 1.84
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst (2004) 1.80
An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc Natl Acad Sci U S A (2008) 1.77
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol (2005) 1.68
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine (2010) 1.67
Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother (2006) 1.60
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother (2008) 1.57
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Localization of ventricular tachycardia exit site and subsequent contraction sequence and functional effects with bedside radionuclide angiography. JACC Cardiovasc Imaging (2008) 1.51
Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell (2006) 1.51
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin Vaccine Immunol (2009) 1.46
Spontaneous intracranial hypotension: recommendations for management. Can J Neurol Sci (2013) 1.41
Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin Diagn Lab Immunol (2005) 1.40
HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology (2009) 1.38
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol (2005) 1.36
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A (2014) 1.32
Chytridiomycosis in native Arizona frogs. J Wildl Dis (2002) 1.32
Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr Protoc Immunol (2007) 1.30
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail (2010) 1.27
Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease. Clin Vaccine Immunol (2010) 1.25
Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. J Med Chem (2007) 1.25
Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J Immunol (2011) 1.24
The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency. J Virol (2004) 1.22
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol (2007) 1.22
Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine (2009) 1.22
Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. J Virol (2009) 1.21
Varicella-Zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response. J Virol (2007) 1.18
Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. J Virol (2002) 1.17
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis (2009) 1.17
Restructuring within an academic health center to support quality and safety: the development of the Center for Quality and Safety at the Massachusetts General Hospital. Acad Med (2009) 1.16
Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother (2006) 1.14
Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood (2003) 1.14
Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology (2006) 1.13
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol (2010) 1.12
In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors. Antimicrob Agents Chemother (2004) 1.12
Acute intravenous--intra-arterial revascularization therapy for severe ischemic stroke. Stroke (2002) 1.10
Binding of FADD and caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function. J Virol (2002) 1.09
Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine (2008) 1.08
Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. Radiother Oncol (2011) 1.07
Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem (2009) 1.07
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A (2004) 1.06
Varicella-zoster virus immediate-early 63 protein interacts with human antisilencing function 1 protein and alters its ability to bind histones h3.1 and h3.3. J Virol (2008) 1.06
Varicella-zoster virus (VZV) ORF17 protein induces RNA cleavage and is critical for replication of VZV at 37 degrees C but not 33 degrees C. J Virol (2002) 1.05
LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. Mol Biosyst (2011) 1.04
Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol (2009) 1.03
Interleukin 17 modulates the immune response to vaccinia virus infection. Virology (2002) 1.03
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood (2010) 1.03
The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology (2004) 1.02
Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol (2008) 1.02
Postattachment events associated with viral entry are necessary for induction of interferon-stimulated genes by human cytomegalovirus. J Virol (2004) 1.02
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J (2012) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
Varicella-zoster virus open reading frame 21, which is expressed during latency, is essential for virus replication but dispensable for establishment of latency. J Virol (2003) 1.01
Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus. J Virol (2006) 1.01
Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J Med Chem (2004) 1.01
Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C. Clin Diagn Lab Immunol (2005) 1.01
Molecular model for astringency produced by polyphenol/protein interactions. Biomacromolecules (2004) 1.01
DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res (2003) 1.00
Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J Biomol Screen (2008) 0.99
Perforin and lymphohistiocytic proliferative disorders. Br J Haematol (2005) 0.99
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J (2009) 0.98
RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother (2002) 0.97
Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother (2004) 0.97
Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog (2011) 0.97
Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett (2005) 0.95
Unraveling condition specific gene transcriptional regulatory networks in Saccharomyces cerevisiae. BMC Bioinformatics (2006) 0.95
Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule. J Virol (2004) 0.95